Waters Corp

Waters Corporation powers pharma and environmental research with high‑performance liquid chromatography and mass‑spectrometry, driving 5.8% revenue growth, strong margins, and resilient free cash flow.

Waters Corp’s Q4 results show modest revenue growth, EPS beating expectations, and a shift to subscription sales—highlighting its BD merger’s impact and future growth strategy.

Waters Corp’s Q4 2025 earnings hit $1.05B, spurred by high‑throughput chemistry tools and a new Empower subscription model, while its $18B BD Biosciences deal positions it for future diagnostics growth—despite short‑term revenue dips.

Institutional investors back Waters Corp as it expands digital chemistry and service‑based revenue, positioning itself for growth in the $1.3 bn global HPLC market.

Waters Corp. gains “Outperform” upgrades and bullish RSI as its LC‑MS innovations, FDA clearance, and strategic biopharma partnership boost investor confidence.

Waters Corp’s stock hits new highs—boosted by a strong pipeline, 12% revenue growth, and an “Outperform” upgrade, positioning it ahead of peers in analytical tech.

Waters Corporation has reported positive financial results for the second quarter, exceeding street estimates and raising its full-year 2025 guidance.

Waters Corporation’s stock price has demonstrated stability, with a premium valuation reflecting investors’ confidence in its future growth prospects.

Waters Corp has announced a strategic partnership with Becton Dickinson, merging a Becton Dickinson unit with Waters’ Biosciences & Diagnostic Solutions division to create a leading bioscience and diagnostics company.

Waters Corp has announced a $17.5 billion partnership with Becton Dickinson, set to create a medical testing giant with a projected $40 billion addressable market.